A B S T R A C TThe neuroendocrine differentiation in PC could potentially represent a new finding with diagnostic,prognostic and therapeutic implications. This study aimed at evaluating the clinical usefulness of CgA as aneuroendocrine (NE) serum-marker. We investigated the role of the serum concentration of CgA in astudy group of patients with PC. CgA was significantly higher in the patients affected by PC as comparedwith the group of healthy subjects (HS) and those with chronic pancreatitis (CHP) (p < 0.001). Also the HSgroup differed significantly from the CHP control group in the serum CgA levels (p < 0.001). The serumcarbohydrate antigen (CA19-9) level displayed a significant difference (p < 0.001) between the PC andthe HS group. The PC and CHP groups, as well as the HS and CHP groups showed also significantdifferences in the CA19-9 levels (p < 0.001). One can conclude that the patients with higher CgA levelshad poorer prognosis and survival, as compared to those with lower CgA levels. These results support thenotion that the determination of serum CgA level before treatment may be a potential prognostic factorfor PC.

Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer

MALAGUARNERA, Mariano;ALESSANDRIA, Innocenza Rosanna;LUCA, Salvatore;MOTTA, Massimo
2009-01-01

Abstract

A B S T R A C TThe neuroendocrine differentiation in PC could potentially represent a new finding with diagnostic,prognostic and therapeutic implications. This study aimed at evaluating the clinical usefulness of CgA as aneuroendocrine (NE) serum-marker. We investigated the role of the serum concentration of CgA in astudy group of patients with PC. CgA was significantly higher in the patients affected by PC as comparedwith the group of healthy subjects (HS) and those with chronic pancreatitis (CHP) (p < 0.001). Also the HSgroup differed significantly from the CHP control group in the serum CgA levels (p < 0.001). The serumcarbohydrate antigen (CA19-9) level displayed a significant difference (p < 0.001) between the PC andthe HS group. The PC and CHP groups, as well as the HS and CHP groups showed also significantdifferences in the CA19-9 levels (p < 0.001). One can conclude that the patients with higher CgA levelshad poorer prognosis and survival, as compared to those with lower CgA levels. These results support thenotion that the determination of serum CgA level before treatment may be a potential prognostic factorfor PC.
2009
Pancreatic cancer Neuroendocrine components Chromogranin A Carbohydrate antigen (CA19-9)
File in questo prodotto:
File Dimensione Formato  
cgA.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 256.57 kB
Formato Adobe PDF
256.57 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/9147
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
social impact